• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

冰岛10年致命性心血管疾病和冠心病风险评估,结果与系统性冠心病风险评估项目相当。

Estimation of 10-year risk of fatal cardiovascular disease and coronary heart disease in Iceland with results comparable with those of the Systematic Coronary Risk Evaluation project.

作者信息

Aspelund Thor, Thorgeirsson Gudmundur, Sigurdsson Gunnar, Gudnason Vilmundur

机构信息

The Icelandic Heart Association, Kopavogur bLandspitali-University Hospital, Reykjavik, Iceland.

出版信息

Eur J Cardiovasc Prev Rehabil. 2007 Dec;14(6):761-8. doi: 10.1097/HJR.0b013e32825fea6d.

DOI:10.1097/HJR.0b013e32825fea6d
PMID:18043296
Abstract

BACKGROUND

No data are available on the comparison between an absolute 10-year risk of fatal cardiovascular disease (CVD) and coronary heart disease (CHD) morbidity using the risk assessments of the Systematic Coronary Risk Evaluation (SCORE) project.

DESIGN

Data from the prospective Reykjavik Study of 15,782 patients were used to estimate the 10-year risk of fatal CVD and CHD morbidity in Iceland.

METHODS

Survival to fatal CVD event was defined as in the SCORE project. Survival to CHD morbidity was defined as having a myocardial infarction, coronary artery bypass graft, or angioplasty. The statistical methodology of SCORE was used.

RESULTS

Relative risk in Iceland was comparable with SCORE results but baseline risk was similar to the low-risk version of SCORE, which contradicted previous suggestions for the countries of northern Europe. Correlation between absolute risk of CHD morbidity and risk for fatal CVD was high (r=0.96), resulting in similar ranking of individuals by risk and discriminatory capacity. This is the first published comparison between total fatal CVD risk and CHD morbidity in a population-based cohort using the current risk assessment guidelines of the European Societies on Coronary Prevention.

CONCLUSIONS

Risk for fatal CVD in Iceland has the same characteristics as those in a European nation with results varying in accordance with the SCORE project. The risk estimate to be used, CHD morbidity or fatal CVD, is a choice of clinical preference. The data, however, suggest that 5% high-risk threshold of fatal CVD corresponds to a 12% CHD-morbidity risk, which is a significant change from the conventional reference value of 20%.

摘要

背景

尚无关于使用系统性冠状动脉风险评估(SCORE)项目的风险评估来比较致命性心血管疾病(CVD)的绝对10年风险与冠心病(CHD)发病率的数据。

设计

来自对15782名患者的前瞻性雷克雅未克研究的数据用于估计冰岛致命性CVD和CHD发病率的10年风险。

方法

致命性CVD事件的生存情况定义同SCORE项目。CHD发病的生存情况定义为发生心肌梗死、冠状动脉搭桥术或血管成形术。使用SCORE的统计方法。

结果

冰岛的相对风险与SCORE结果相当,但基线风险与SCORE的低风险版本相似,这与之前对北欧国家的建议相矛盾。CHD发病的绝对风险与致命性CVD风险之间的相关性很高(r = 0.96),导致个体按风险和鉴别能力的排名相似。这是首次使用欧洲冠状动脉预防协会的当前风险评估指南,在基于人群的队列中对总致命性CVD风险和CHD发病率进行的比较。

结论

冰岛致命性CVD的风险与欧洲国家具有相同特征,结果根据SCORE项目而有所不同。要使用的风险估计值,即CHD发病率或致命性CVD,是临床偏好的选择。然而,数据表明,致命性CVD的5%高风险阈值对应于12%的CHD发病风险,这与20%的传统参考值有显著变化。

相似文献

1
Estimation of 10-year risk of fatal cardiovascular disease and coronary heart disease in Iceland with results comparable with those of the Systematic Coronary Risk Evaluation project.冰岛10年致命性心血管疾病和冠心病风险评估,结果与系统性冠心病风险评估项目相当。
Eur J Cardiovasc Prev Rehabil. 2007 Dec;14(6):761-8. doi: 10.1097/HJR.0b013e32825fea6d.
2
Independent impact of gout on mortality and risk for coronary heart disease.痛风对死亡率和冠心病风险的独立影响。
Circulation. 2007 Aug 21;116(8):894-900. doi: 10.1161/CIRCULATIONAHA.107.703389. Epub 2007 Aug 13.
3
The impact of birth weight on coronary heart disease morbidity and mortality in a birth cohort followed up for 85 years: a population-based study of men born in 1913.对一个随访了85年的出生队列研究出生体重对冠心病发病率和死亡率的影响:一项基于1913年出生男性的人群研究
J Intern Med. 2004 Dec;256(6):472-81. doi: 10.1111/j.1365-2796.2004.01412.x.
4
Validity of the Framingham point scores in the elderly: results from the Rotterdam study.弗雷明汉积分在老年人中的有效性:鹿特丹研究结果
Am Heart J. 2007 Jul;154(1):87-93. doi: 10.1016/j.ahj.2007.03.022.
5
Evaluation of a recalibrated Systematic Coronary Risk Evaluation cardiovascular risk chart: results from Systematic Coronary Risk Evaluation Germany.重新校准的系统性冠状动脉风险评估心血管风险图表的评估:来自德国系统性冠状动脉风险评估的结果
Eur J Cardiovasc Prev Rehabil. 2008 Aug;15(4):409-15. doi: 10.1097/HJR.0b013e3282feec66.
6
The association between socioeconomic status of high-risk patients with coronary heart disease and the treatment rates of evidence-based medicine for coronary heart disease secondary prevention in China: Results from the Bridging the Gap on CHD Secondary Prevention in China (BRIG) Project.中国冠心病高危患者的社会经济地位与冠心病二级预防循证医学治疗率之间的关联:中国冠心病二级预防弥合差距(BRIG)项目的结果
Am Heart J. 2009 Apr;157(4):709-15.e1. doi: 10.1016/j.ahj.2008.12.009. Epub 2009 Jan 31.
7
What impact will current trial data have on future guideline recommendations?当前的试验数据将对未来的指南建议产生怎样的影响?
Am J Med. 2005 Dec;118 Suppl 12A:42-7. doi: 10.1016/j.amjmed.2005.09.005.
8
Comparison of three different methods of assessing cardiovascular disease risk in New Zealanders with Type 2 diabetes mellitus.新西兰2型糖尿病患者三种不同心血管疾病风险评估方法的比较。
N Z Med J. 2008 Sep 5;121(1281):49-57.
9
Adherence to a DASH-style diet and risk of coronary heart disease and stroke in women.女性坚持得舒饮食法与冠心病和中风风险
Arch Intern Med. 2008 Apr 14;168(7):713-20. doi: 10.1001/archinte.168.7.713.
10
Cardiovascular disease risk profiles among 'healthy' siblings of patients with early-onset cardiovascular disease: application of the new SCORE system.早发性心血管疾病患者“健康”兄弟姐妹的心血管疾病风险概况:新SCORE系统的应用
Eur J Cardiovasc Prev Rehabil. 2007 Aug;14(4):521-5. doi: 10.1097/HJR.0b013e328011c493.

引用本文的文献

1
Prediabetes and cardiovascular risk factors: the effectiveness of a guided self-determination counselling approach in primary health care, a randomized controlled trial.糖尿病前期和心血管危险因素:初级卫生保健中引导自主决策咨询方法的有效性,一项随机对照试验。
BMC Public Health. 2024 Nov 1;24(1):3035. doi: 10.1186/s12889-024-20538-1.
2
Risk estimation for the primary prevention of cardiovascular disease: considerations for appropriate risk prediction model selection.心血管疾病一级预防的风险评估:适当风险预测模型选择的考虑因素。
Lancet Glob Health. 2024 Aug;12(8):e1343-e1358. doi: 10.1016/S2214-109X(24)00210-9.
3
SCORE and SCORE2 in East Asian Population: A Performance Comparison.
东亚人群中的SCORE和SCORE2:性能比较
JACC Asia. 2023 Dec 26;4(4):265-274. doi: 10.1016/j.jacasi.2023.10.013. eCollection 2024 Apr.
4
Population distribution of traditional and the emerging cardiovascular risk factors carotid plaque and IMT: the REFINE-Reykjavik study with comparison with the Tromsø study.传统及新出现的心血管危险因素(颈动脉斑块和内膜中层厚度)的人群分布:雷克雅未克REFINE研究及与特罗姆瑟研究的比较
BMJ Open. 2018 May 31;8(5):e019385. doi: 10.1136/bmjopen-2017-019385.
5
Comparison of validation and application on various cardiovascular disease mortality risk prediction models in Chinese rural population.比较各种心血管疾病死亡风险预测模型在中国农村人群中的验证和应用。
Sci Rep. 2017 Mar 24;7:43227. doi: 10.1038/srep43227.
6
Fish and fish-liver oil consumption in adolescence and midlife and risk of CHD in older women.青春期和中年时期鱼类及鱼肝油的摄入量与老年女性冠心病风险
Public Health Nutr. 2016 Feb;19(2):318-25. doi: 10.1017/S1368980015001020. Epub 2015 Apr 17.
7
Cardiovascular risk assessment: a global perspective.心血管风险评估:全球视角。
Nat Rev Cardiol. 2015 May;12(5):301-11. doi: 10.1038/nrcardio.2015.28. Epub 2015 Mar 10.
8
Population assessment of future trajectories in coronary heart disease mortality.冠心病死亡率未来轨迹的人群评估。
PLoS One. 2014 Jan 21;9(1):e85800. doi: 10.1371/journal.pone.0085800. eCollection 2014.
9
SCORE performance in Central and Eastern Europe and former Soviet Union: MONICA and HAPIEE results.在中东欧和前苏联的 SCORE 表现:MONICA 和 HAPIEE 研究结果。
Eur Heart J. 2014 Mar;35(9):571-7. doi: 10.1093/eurheartj/eht189. Epub 2013 Jun 20.
10
Similar decline in mortality rate of older persons with and without type 2 diabetes between 1993 and 2004 the Icelandic population-based Reykjavik and AGES-Reykjavik cohort studies.1993 年至 2004 年间,冰岛人群为基础的雷克雅未克和年龄雷克雅未克队列研究中,2 型糖尿病患者和非 2 型糖尿病患者的死亡率均呈类似下降趋势。
BMC Public Health. 2013 Jan 15;13:36. doi: 10.1186/1471-2458-13-36.